FARAPULSE Ablation for Atrial Fibrillation
(ReMATCH Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The ReMATCH Study is a prospective, single arm, open label, multi-center, study utilizing the FARAPULSE PFA System, including the FARAWAVE and FARAPOINT PFA Catheters.
Who Is on the Research Team?
Moussa Mansour,, MD
Principal Investigator
Massachusetts General Hospital
Are You a Good Fit for This Trial?
This trial is for people who've had one atrial fibrillation ablation within the last 5 years and have persistent AF, documented by a monitoring device, that doesn't stop after 7 days or needs cardioversion. Participants must be able to give informed consent and commit to all follow-up tests at an approved center.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo repeat ablation of persistent atrial fibrillation using the FARAPULSE PFA System
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- FARAPULSE Pulsed Field Ablation System
Find a Clinic Near You
Who Is Running the Clinical Trial?
Boston Scientific Corporation
Lead Sponsor
Michael F. Mahoney
Boston Scientific Corporation
Chief Executive Officer since 2016
MBA from Wake Forest University, BBA in Finance from the University of Iowa
Kenneth Stein
Boston Scientific Corporation
Chief Medical Officer since 2020
MD from Harvard Medical School, MMSc in Clinical Investigation from Harvard-MIT Division of Health Sciences and Technology